DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up

Information source: Helsinki University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Atopic Dermatitis

Intervention: Histamine provocation (Procedure); Skin prick tests (Procedure); Serum IgE blood testing (Procedure); Mantoux-testing (Procedure)

Phase: N/A

Status: Completed

Sponsored by: Helsinki University

Official(s) and/or principal investigator(s):
Sakari Reitamo, MD, PhD, Principal Investigator, Affiliation: Skin- and Allergy Hospital, Dep. of Dermatology

Summary

The investigators will contact 64 patients with atopic dermatitis (AD) who participated in a long-term tacrolimus ointment trial in Helsinki 10 years ago, and ask them to participate in this follow-up study. The investigators will do the same tests as 10 years ago, i. e. bronchial hyperreactivity, skin prick tests, serum-IgE, Mantoux-test (2 TU), and questionnaires about asthma and allergic rhinitis symptoms. The investigators also collect data about their AD medication during the last 10 years. The investigators hypothesis is that when the skin condition improves in patients with AD the brochial hyperreactivity improves. The investigators also want to study whether different treatments play a role in the development or resolution of bronchial hyperreactivity.

Clinical Details

Official title: Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up

Study design: Observational Model: Cohort

Primary outcome: Bronchial hyperreactivity

Secondary outcome:

Skin prick tests

Serum-IgE

Mantoux-test

Detailed description: We will by letters and telephone contact all patients (n=64) who fulfill the inclusion criteria for this study. The testing in the study (bronchial hyperreactivity, skin prick testing, serum IgE) is cross-sectional, but we retrospectively collect data from the last 10 years about the skin condition and medication for atopic diseases.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patient has participated in the FG-506-06-21 study in Helsinki

- Patient was tested for bronchial hyperreactivity in the years 1998-2000

- Patient gives signed informed consent to participate in this study

Locations and Contacts

Skin- and Allergy Hospital, Department of Dermatology, Helsinki 00250, Finland
Additional Information

Related publications:

Virtanen H, Remitz A, Malmberg P, Rytilä P, Metso T, Haahtela T, Reitamo S. Topical tacrolimus in the treatment of atopic dermatitis--does it benefit the airways? A 4-year open follow-up. J Allergy Clin Immunol. 2007 Dec;120(6):1464-6. Epub 2007 Oct 1.

Starting date: November 2008
Last updated: April 19, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017